Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Ave
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
17
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,111.10 | 82.30 | 0.91% |
CAC 40 | 7,633.81 | 12.77 | 0.17% |
DAX 40 | 23,903.35 | 57.28 | 0.24% |
Dow JONES (US) | 44,167.99 | 56.25 | 0.13% |
FTSE 100 | 9,161.07 | 18.34 | 0.20% |
HKSE | 24,910.63 | 8.10 | 0.03% |
NASDAQ | 21,012.30 | 95.75 | 0.46% |
Nikkei 225 | 40,794.86 | 245.32 | 0.60% |
NZX 50 Index | 12,880.16 | 3.12 | 0.02% |
S&P 500 | 6,320.64 | 21.45 | 0.34% |
S&P/ASX 200 | 8,843.70 | 73.30 | 0.84% |
SSE Composite Index | 3,633.99 | 16.40 | 0.45% |